Table 2.
Histological and biological characteristics of the cases included in the biobank.
| All Cases (n = 363) | |
|---|---|
| Consent | |
| Unknown | 70 (19) |
| Yes | 293 (81) |
| Send by e-mail or postal mail, waiting a reply | 54 |
| Cases included at diagnosis | 290 (80) |
| Cases included at 1st relapse | 69 (19) |
| Cases included at multiple relapse | 4 (1) |
| FFPE Blocks per case, median [IQR] | 3 [2–3] |
| Cases with ≥3 FFPE blocks | 177 (49) |
| % of tumor cells, median [range] (n = 240) | 70 [1–100] |
| Cold ischemia, median [IQR], minute (n = 228) | 20 [15–25] |
| ≤15 | 102 (45) |
| >15 and ≤30 | 87 (38) |
| >30 and ≤45 | 33 (14) |
| >45 | 6 (3) |
| Matched frozen tissue | 256 (71) |
| Matched plasma | 49 (14) |
| Matched serum | 16 (4) |
| Matched PBMC | 6 (2) |
| Matched total blood sample | 7 (2) |
| Matched cell pellet | 7 (2) |
| LYMPHOPATH network rereading | 120 (33) |
| Tumor location | |
| Mediastinum | 131 (36) |
| Lymph node | 84 (23) |
| Waldeyer’s ring | 49 (14) |
| Broncho-pulmonary | 48 (13) |
| Orbit/eye | 20 (6) |
| Soft tissue and bone | 12 (3) |
| Salivary gland | 10 (3) |
| Thyroid | 5 (1) |
| Skin | 3 (0.8) |
| Spleen | 1 (0.3) |
| Diagnosis | |
| B-cell lymphoid proliferations and lymphomas | 244 (67) |
| Precursor B-cell neoplasm | 1 (0.3) |
| B-lymphoblastic leukemia/lymphoma, NOS | 1 (0.3) |
| Mature B-cell neoplasms | 243 (67) |
| Diffuse large B-cell lymphoma, NOS | 63 (17) |
| Extranodal marginal zone lymphoma of MALT | 39 (11) |
| Indolent B-cell lymphoma, not classified | 30 (8) |
| Primary mediastinal B-cell lymphoma | 23 (6) |
| Follicular lymphoma | 23 (6) |
| Extraosseous plasmacytoma | 14 (4) |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | 14 (4) |
| Mantle cell lymphoma | 11 (3) |
| Nodular lymphocyte predominant B-cell lymphoma | 7 (2) |
| Large B-cell lymphoma, not classified | 4 (1) |
| Nodal marginal zone lymphoma | 4 (1) |
| Mediastinal Grey Zone Lymphoma | 3 (0.8) |
| Plasmablastic lymphoma | 2 (0.6) |
| Mature B-cell neoplasm, not classified | 2 (0.6) |
| Lymphoplasmacytic lymphoma | 1 (0.3) |
| Lymphomatoid granulomatosis | 1 (0.3) |
| Burkitt Lymphoma | 1 (0.3) |
| Diffuse large B-cell lymphoma associated with chronic inflammation | 1 (0.3) |
| Classic Hodgkin lymphoma | 93 (26) |
| Nodular sclerosis | 54 (15) |
| Not classified | 31 (9) |
| Mixed cellularity | 4 (1) |
| Lymphocytes rich | 3 (0.8) |
| Lymphocytes depleted | 1 (0.3) |
| T-cell and NK-cell lymphoid proliferations and lymphomas | 20 (6) |
| Precursor T-cell neoplasms | |
| T-lymphoblastic leukemia/lymphoma, NOS | 6 (2) |
| Mature T-cell and NK-cell neoplasms | 14 (4) |
| Peripheral T-cell lymphoma, NOS | 4 (1) |
| Extranodal NK/T-cell lymphoma, nasal-type | 4 (1) |
| ALK-negative anaplastic large cell lymphoma | 4 (1) |
| Nodal T-follicular helper (TFH) cell lymphoma, NOS | 2 (0.6) |
| Lymphoid neoplasms, not classified | 5 (1) |
FFPE: formalin-fixed paraffin embedded; IQR: inter-quartile range; PBMC: peripheral blood mononuclear cells; NOS: not otherwise specified.